Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Worldwide Offices
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Astraveus further strengthens world class leadership team to advance development of Lakhesys Benchtop Cell Factory™


News provided by

Astraveus

21 Oct, 2025, 07:30 GMT

Share this article

Share toX

Share this article

Share toX

  • Highly experienced hires bring robust operational and technical expertise
  • Momentum builds at Astraveus following exceptional additions of Jean-Paul Mangeolle, David Newble, and Laurence Riot Lamotte earlier this year

PARIS, Oct. 21, 2025 /PRNewswire/ -- Astraveus SAS ("Astraveus" or the "Company"), the Benchtop Cell Factory company, today announces that it has further strengthened its world class leadership team with the appointments of Didier Masson as Chief Operating Officer, and Ken Kotz as Chief Technology Officer.

Didier Masson brings over 20 years of experience in operations across pharma, biotech, and medtech. He joins from Quantoom Biosciences, where he was also COO. His expertise lies in program management, manufacturing and supply chain across bioprocessing. His operational remit at Astraveus will include the scaling of its innovative Lakhesys Benchtop Cell Factory™, and the development of robust, cross-functional processes to deliver operational excellence and sustainable growth.

Ken Kotz is a seasoned technical leader with more than 20 years of experience driving innovation across life sciences. His expertise spans microfluidic bioprocessing, optical systems design, product development, and cell therapy process development, including autologous cell therapy manufacturing. Prior to joining Astraveus, Ken served as Director Process Development at bluebird bio, contributing significantly to the commercialization of Lyfgenia™, as well as leading long-term strategy efforts.

Jérémie Laurent, PhD, Chief Executive Officer, commented: "Didier and Ken both bring exceptional and varied qualities and experience to our leadership team and they will have a pivotal role as we progress the development of our Lakhesys Benchtop Cell Factory. Attracting this level of talent is testament to our ambition, as we endeavor to make these groundbreaking treatments available to everyone in need, thereby enabling a healthier tomorrow."

Didier Masson, newly appointed Chief Operating Officer, added: "I see a tremendous opportunity to contribute to the growth of Astraveus by optimizing operations, building scalable systems, and promoting collaboration across teams. The company's mission and its highly innovative approach truly resonate with me, and I look forward to helping drive operational excellence to support its ambitious goals."

Ken Kotz, PhD, newly appointed Chief Technology Officer, said: " Astraveus' closed, automated, and truly end-to-end approach to cell therapy manufacturing has the potential to transform the autologous cell and gene therapy landscape. I am deeply passionate about helping to expand access to these transformative medicines for patients in need."

These new hires herald a transformational period for Astraveus and complement the existing skillsets of the Company's leadership team. These were bolstered earlier this year with the appointments of Jean-Paul Mangeolle as Chairman of the Board of Directors, David Newble as Independent Board Member, and Laurence Riot Lamotte as Chief Financial Officer. With the integration of this world class leadership team, Astraveus stands at the cusp of revolutionizing the cell therapy manufacturing landscape with its unique Lakhesys Benchtop Cell Factory™.

About Astraveus:

Astraveus is a Paris-based life science company dedicated to scaling cell therapy manufacturing with maximized quality and increased speed at order-of-magnitude lower cost. With the unique Lakhesys Benchtop Cell Factory™, Astraveus provides bioprocessing innovation at the cellular level, utilizing cutting-edge microfluidic technology to enhance process optimization and scalability from pre-clinical to commercial manufacturing.

Founded in 2016 by Jérémie Laurent at the Saint-Louis Hospital in Paris, a prestigious hub for leading cell therapy research, Astraveus is committed to revolutionizing the development and manufacturing of cell therapies and aspires to make these innovative treatments accessible to everyone in need, thereby enabling a healthier tomorrow.

www.astraveus.com

About Didier Masson:

Didier is an operations leader with 25 years of experience in leading cross‑functional teams in the pharma, biotech and medtech industries. He has successfully overseen large-scale operational transformations, aligning execution with business strategy, optimizing processes, and leveraging best project management practices to streamline program execution. Prior to joining Astraveus, Didier held senior roles at IBA, Advanced Oncotherapy, UCB and Quantoom Biosciences, where he led program management, manufacturing, supply chain and field services. His know-how includes industrialization of instrumentation for biopharma manufacturing in compliance with GMP and ISO standards such as ISO13485. He graduated from the University of Liege in Belgium with an MSc in Electrical Engineering, supplemented by a MSc in Management from Louvain School of Management, UCLouvain.

About Ken Kotz:

Ken is a seasoned technical leader with more than 20 years of experience driving innovation across the life sciences industry. His expertise spans microfluidic bioprocessing, optical systems design, product development, and cell therapy process development. Prior to joining Astraveus, Ken held senior positions at bluebird bio, Draper, and Massachusetts General Hospital, and he co-founded General Fluidics, a clinical diagnostics company. Ken has deep expertise in autologous cell therapy manufacturing, contributed significantly to the commercialization of Lyfgenia™ at bluebird bio, and led long-term strategy efforts to advance next-generation autologous manufacturing. Ken earned his BSc in Chemistry from the University of Michigan and his PhD in Physical Chemistry from the University of California, Berkeley.

Modal title

Also from this source

Astraveus Enters Strategic Partnership with NecstGen to evaluate Lakhesys Benchtop Cell Factory™ for CAR-T therapy manufacturing

Astraveus SAS ("Astraveus" or the "Company"), the benchtop cell factory company, today announces that it has entered into a strategic partnership...

Astraveus Strengthens Leadership Team and Board

Astraveus SAS ("Astraveus" or the "Company"), the Benchtop Cell Factory company, today announces that it has strengthened its leadership team and...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Computer & Electronics

Computer & Electronics

Biotechnology

Biotechnology

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • PR Newswire Amplify™
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.